MedPath

Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome

Phase 1
Recruiting
Conditions
Comparative Study
Interventions
Registration Number
NCT06199544
Lead Sponsor
Hamdard University
Brief Summary

Currently available medications for PCOS are symptom(s) oriented but have limitations because of its complex pathophysiology. The most preferred drug against PCOS is metformin which act as an insulin sensitizer to improve insulin-glucose metabolism and anovulatory cycles in PCOS. However, its use is associated with various side effects such as bloating, diarrhea and nausea. Thus, it is imperative to explore various other alternatives to combat this gynecological problem.

Detailed Description

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in reproductive age women, with a prevalence between 5%-15%. Currently, sedentary lifestyle, excessive intake of junk food and increasing prevalence of obesity has been associated with rise in the incidence of PCOS.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RasolineMetforminRasoline 500mg thrice a day
Picolin groupMetforminPicolin 500mg thrice a day
Control groupMetforminmetformin 500 mg twice a day
Primary Outcome Measures
NameTimeMethod
Improvement in the menstrual regularity of the patient1 year

The lengths and duration of menstrual cycle of patients will be measured

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shifa ul mulk memorial hospital

🇵🇰

Karachi, Sindh, Pakistan

© Copyright 2025. All Rights Reserved by MedPath